O
Oblique Therapeutics
Combination immunotherapy to fight cancer
About Oblique Therapeutics
Oblique Therapeutics is a Swedish biotechnology company that is developing new medicines for severe diseases with a large unmet medical need. The company is focused on pain and aggressive-metastatic cancer. Oblique Therapeutics was founded by Owe Orwar, who has a PhD in biomedical research from the University of Copenhagen and did his post-doctoral training at the Institute Pasteur in Paris.
The company has developed a proprietary antibody discovery platform called AbiProt®. This platform is used to develop new antibody-based therapies. The company has a pipeline of eleven programs, with a focus on pain and aggressive-metastatic cancer. One of the company's programs is targeting the TRPV1 ion channel for the treatment of pain.
The company's business model is to develop new medicines and then partner with larger pharmaceutical companies to bring them to market. The company has a research collaboration with Eli Lilly. The company's clients are large pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Göteborgs Stad, Sweden
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 57.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Immune System, Hospital, Biotech and Pharma, Nordic Rising Star 2022, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jun 2026 | $1.7M | — | Undisclosed | ↗ |
| CONVERTIBLE✓Equity / VC | Jul 2025 | $1.8M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Oblique Therapeutics is 4.8K monthly website visits, up 100% over the last three months. Oblique Therapeutics's team declined 35.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Almi Invest
Sunstone Life Science Ventures
Västra Hamnen
Other known investors3 additional known investors
Almi Företagspartner
Midroc New Technology
STOAF
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Oblique Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Oblique Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.